Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer

ConclusionsThese VEGF-related polymorphisms were found to be associated with HFSR and the survival benefits of regorafenib treatment.Trial registration number and dateUMIN000013939, registered on May 12, 2014, when 6  months after the approval by the Institutional Review Board of Showa University.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research